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Abstract: High-fat diets (HFD) have been widely associated with an increased risk of metabolic
disorders and overweight. However, a high intake of sources that are rich in monounsaturated fatty
acids has been suggested as a dietary agent that is able to positively influence energy metabolism and
vascular function. The main objective of this study was to analyze the role of dietary fats on hepatic
peptidases activities and metabolic disorders. Three diets: standard (S), HFD supplemented with
virgin olive oil (VOO), and HFD supplemented with butter plus cholesterol (Bch), were administered
over six months to male Wistar rats. Plasma and liver samples were collected for clinical biochemistry
and aminopeptidase activities (AP) analysis. The expression of inducible nitric oxide synthase (iNOS)
was also determined by Western blot in liver samples. The diet supplement with VOO did not induce
obesity, in contrast to the Bch group. Though the VOO diet increased the time that was needed to
return to the basal levels of plasma glucose, the fasting insulin/glucose ratio and HOMA2-%B index
(a homeostasis model index of insulin secretion and valuation of β-cell usefulness (% β-cell secretion))
were improved. An increase of hepatic membrane-bound dipeptidyl-peptidase 4 (DPP4) activity was
found only in VOO rats, even if no differences in fasting plasma glucagon-like peptide 1 (GLP-1)
were obtained. Both HFDs induced changes in hepatic pyroglutamyl-AP in the soluble fraction, but
only the Bch diet increased the soluble tyrosyl-AP. Angiotensinase activities that are implicated in the
metabolism of angiotensin II (AngII) to AngIV increased in the VOO diet, which was in agreement
with the higher activity of insulin-regulated-AP (IRAP) in this group. Otherwise, the diet that was
enriched with butter increased soluble gamma-glutamyl transferase (GGT) and Leucyl-AP, iNOS
expression in the liver, and plasma NO. In summary, VOO increased the hepatic activity of AP
that were related to glucose metabolism (DPP4, angiotensinases, and IRAP). However, the Bch diet
increased activities that are implicated in the control of food intake (Tyrosine-AP), the index of hepatic
damage (Leucine-AP and GGT), and the expression of hepatic iNOS and plasma NO. Taken together,
these results support that the source of fat in the diet affects several peptidases activities in the liver,
which could be related to alterations in feeding behavior and glucose metabolism.
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1. Introduction
Obesity is considered a serious chronic disease with adverse consequences due to the excessive
accumulation of adipose tissue. Usually, obesity is caused by an imbalance between energy intake
and energy expenditure [1]. The prevalence of obesity in the population has increased alarmingly in
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the past few decades, and it typically it is a part of a cluster of metabolic syndrome conditions that
increase the chance of developing several related disorders, such as type 2 diabetes, dyslipidemia,
abnormal cholesterol levels, hypertension, stroke, heart disease, and cancer [2,3]. Several studies have
documented a positive relationship between a high-fat diet (HFD) intake and obesity [4]. The efficacy of
the current strategies of treatment for diseases that are caused by obesity is still not entirely satisfactory,
and new approaches must be considered. Several studies have indicated relationships between the
saturation of dietary fat and the concentrations of total plasma cholesterol and higher blood pressure [5],
hepatic steatosis [6], adipose chronic inflammation [6], ectopic lipid deposition in the liver and brown
fat [6], overweight [6,7], hyperinsulinemia [7], and hepatic insulin resistance [8]. However, high fat
diets that are rich in monounsaturated fatty acids exert a protective role [9–15].
High monounsaturated fatty acids diets also have demonstrated an effect on the secretion of
the insulinotropic peptide GLP-1 (glucagon-like peptide 1) [16,17]. GLP-1 is an incretin hormone
with antidiabetic action that is capable of stimulating insulin secretion [18,19], increasing beta cell
neogenesis [20], inhibiting beta cell apoptosis [20], inhibiting glucagon secretion [21], delaying gastric
emptying, and inducing satiety [20,21]. However, the physiological inhibitory control of GLP-1 and its
accelerated inactivation by plasma dipeptidyl-peptidase 4 (DPP4) hyperactivity [22] suggests that the
impaired secretion and/or activity of GLP-1 may be involved in the pathogenesis of obesity [23].
The renin–angiotensin system (RAS) is an important regulator of blood pressure, electrolytes,
and water balance. Until recently, angiotensin II (Ang II) was considered the main peptide that is
involved in these homeostatic mechanisms. However, some of its metabolic derivatives such as
angiotensin III (Ang III), angiotensin IV (Ang IV), and angiotensin 2-10 (Ang 2-10) have demonstrated
important biological functions [24] (Figure 3A). The main peptides of the RAS (AngII and AngIII)
bind to both AT1- and AT2-receptors with similar affinity [25,26]. In contrast, the affinity of Ang
IV for the well-characterized AT1- and AT2-receptors is low [25], but it shows a high affinity to the
AT4-receptor/insulin-regulated aminopeptidase (IRAP) [27]. Ang IV, which binds to IRAP (Figure 3A),
appears to play a role in regulating local blood flow [28]. Local RASs could be altered by different
degrees of saturation in dietary fat. Angiotensin peptides are metabolized by several angiotensinases,
and we have previously demonstrated that those activities are affected by dietary fatty acids [5,29,30].
The local RAS in the liver plays an important role in the paracrine and autocrine regulation of
hepatocyte metabolism [31], and all the components of this system have been described in hepatic
cells [32–34]. Under pathological conditions, the role of the liver’s RAS appears to be more important.
Local angiotensin peptides increase cell proliferation, apoptosis, and the production of oxygen reactive
species [35]. The Western diet induces liver steatosis and is also associated with the alteration of the
local RAS in hepatocytes [36], and both renal and hepatic local RASs seem to be implicated in the
development of chronic liver disease [37].
Lipids are recognized to be associated with the intracellular generation of reactive oxygen species
(ROS) [38] as support for oxidative damage. The HFD, and subsequent dyslipidemia, are the major
triggers for oxidative stress, and the increase of gamma-glutamyl transferase (GGT) like hepatic
function biomarker [39]. Nitric oxide (NO) exerts a protective effect on liver diseases and hepatotoxicity
that is associated with HFD [40,41]. The hepatic inducible isoform of the NO synthase (iNOS) functions
as an adaptive response to minimize inflammatory injury [40,41].
The thyrotropin-released hormone (TRH)-degrading pyroglutamate aminopeptidase (pGluAP)
activities convert TRH into cyclo His-Pro (cHP) [42], a potential hypoglycemic dipeptide that restores
glucose metabolism, the blood insulin level, the lipid profile, and impaired β-cells in the pancreas [43].
Previous results suggested that the type of fat that is used in the diet may influence local pGluAP
activity and modify its biological functions [44]. Other studies have implicated opioid transmission
in the hedonic and metabolic control of feeding and diet-induced obesity [45]. Enkephalin (ENK)
concentration changes in liver tissue and plasma during liver disorders [46,47], after a high-fat meal
with an increased propensity to overeat [48], and with a higher systolic blood pressure [49]. ENK is
hydrolyzed by specific enzymes, such as the ENK-degrading tyrosyl aminopeptidase (TyrAP) [50].
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Then, hepatic TyrAP activity could be an index to evaluate the potential value of ENK degradation as
a biological marker of the hedonic control and progression of obesity disorders.
In order to analyze the effects of HFD on liver peptide metabolism, we administered diets with
different amounts and fat sources to rat groups in this study. We demonstrate that monounsaturated
HFD is not related to metabolic manifestations because overweight, dyslipidemia, and high cholesterol
levels were present in the animals that were fed with a saturated HFD. However, monounsaturated
HFD mainly affects parameters that are related to glucose metabolism, probably in agreement with
a greater use of fatty acids for energy. At the same time, the analyzed diets had a differential effect on
several aminopeptidase activities with important roles in the development of metabolic syndromes.
2. Materials and Methods
2.1. Animals and Treatments
Adult male Wistar rats were purchased from Harlan Interfauna Ibérica S.A. (Barcelona, Spain).
The rats had free access to experimental diets and water during 24 weeks, and they were maintained at
a controlled temperature (20–25 ◦C) and humidity (50 ± 5%) environment in a 12 hours light/dark cycle.
At the beginning of the study, the mean body weight and age were 495 g and six months, respectively.
Experimental procedures for animal use and care were in accordance with European Communities
Council Directive 2010/63/UE and Spanish regulation RD 53/2013, and the study was approved by the
Institutional Animal Care and Use Committee of the University of Jaén. Rats were randomly assigned
into three groups (n = 5 each): In the standard diet (S) group, rats were fed with a commercial chow
for experimental animals. In HFDs, one group of rats was fed with a diet supplemented with 20%
of virgin olive oil (VOO), and the second group of rats was fed with a diet supplemented with 20%
butter plus cholesterol (0.1%) (Bch) in order to reach the average cholesterol content of the Western
diet. The HFD diets were isocaloric. The food composition and nutritive value of different diets are
shown in Supplemental Table S1. The food intake for each group was measured, and the animals were
weighed once a week. At the end of the experimental period, a glucose tolerance test was performed.
Animals were perfused with a saline solution through the left cardiac ventricle under Equithensin
anesthesia (2 mL/kg Body Weight), and a sample of blood was collected for GLP-1, insulin, NO and
other biochemical parameters. The blood samples were centrifuged for 10 min at 2000 g to obtain the
plasma. Liver tissue samples were collected for angiotensinase activities, ENK- and TRH-degrading
activities, hepatic damage markers, and immunoblot for hepatic iNOS.
2.2. Glucose Tolerance Test
A glucose tolerance test (GTT) was performed after overnight fasting. For the GTT, rats were i.p.
injected (8 mL/kg BW) with a single dose of glucose that was dissolved in saline (2.0 g/kg BW). Blood
glucose was measured by using a glucometer (Roche Accu-Check Inform.). A baseline (fasting) blood
glucose measurement was taken before glucose administration, and further measurements were made
at regular intervals thereafter (20, 40, 60 and 90 min).
2.3. Determination of Blood Parameters
Plasma insulin levels were determined by using an ELISA kit (#10-1113-01) that was purchased
from Mercodia Developing Diagnostics (Winston Salem, NC, USA). Plasma GLP-1 concentrations were
determined by using an ELISA kit (#107444-51-9) that was purchased from Cayman (Ann Arbor, MI,
USA).
Plasma levels of NO were analyzed by the Griess method as a summation of NO2- and NO3- with
an assay kit (Total Nitric Oxide and Nitrate/Nitrite Parameter#KGE001) that was purchased from R&D
Systems (Minneapolis, MN, USA).
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2.4. Determination of Insulin Resistance
A homeostasis model of insulin resistance (HOMA2-IR) was calculated by using the HOMA
Calculator v.2.2.3 software [51]. HOMA-2 is an update and actualization of the HOMA equation,
where a lineal regression is established between glucose and insulin by adjusting real physiology. It is
possible, with this program, to calculate the HOMA2-%B, an index of insulin secretion and a valuation
of β-cell usefulness (% β-cell secretion), and to know HOMA2-%S, an index for estimating sensitivity
to insulin (% insulin sensitivity).
2.5. Sample Preparation for Aminopeptidase Activities Assay
Plasma samples were used for the peptidase activities assay. Samples from the liver were quickly
removed and frozen in dry ice. To obtain a soluble fraction, tissue samples were homogenized in
ten volumes of a 10 mM HCl-Tris buffer (pH 7.4) and ultracentrifuged (100,000 g for 30 min at 4 ◦C).
The resulting supernatants were used to measure soluble (sol) enzymatic activity and protein content,
assayed in triplicate. To solubilize membrane proteins, pellets were re-homogenized in an HCl-Tris
buffer (pH 7.4) plus Triton X-100 (1%). After centrifugation (100,000 g for 30 min at 4 ◦C), supernatants
were used to measure membrane-bound (mb) activity and proteins in triplicate. To ensure the complete
recovery of activity, detergent (Triton X-100) was removed from the medium by adding the adsorbent
polymeric SM-2 Biobeads (100 mg/mL), which were purchased form Bio-Rad (Richmond, VA, USA),
to the samples and the shaking for 2 h at 4 ◦C [52].
2.6. Peptidase Activities Assay
The DPP4 family, GGT, LeuAP, pGluAP, TyrAP and angiotensinase (AspAP, GluAP, AlaAP,
and IRAP) activities were determined in a fluorometric assay while using arylamidase as substrate
according to the method of Ramírez et al. [53]. The substrate and substrate solution for each activity
are listed in Supplemental Table S2. Briefly, 10 µL of each supernatant were incubated for 30 min
at 37 ◦C with 100 µL of the substrate solution [54]. Later, enzymatic reactions were ceased after
adding 100 µL of a 0.1 M acetate buffer (pH 4.2). The β-naphthylamine (β-NA) that was released as
a product of proteolytic activity was fluorometrically assessed at 412 nm emission and at a 345 nm
excitation wavelength. Specific peptidases activities were expressed as pmol of the β-NA that was
hydrolyzed per minute and per milligram of protein. Fluorogenic assays were linear with respect to
time of hydrolysis and protein concentration. The protein concentration was determined according to
Bradford method [55] with BSA (Bovine Serum Albumin) as standard. All chemical products were
supplied by Sigma (St. Louis, MO, USA).
2.7. Protein Extraction and Western Blot Analysis
For the Western blotting, total protein was isolated from the liver samples. The hepatic tissues
were homogenized in a cooled protein extraction buffer (Tris-HCl, 0.1 M, pH 7.5; aprotinin, 0.1 mg/mL;
sodium pyrophosphate, 0.1 M; sodium fluoride, 0.1 M; EDTA (Ethylene Diamine Tetraacetic Acid),
0.01 M; sodium orthovanadate, 0.01 M; and PMSF (Phenyl Methyl Sulfonyl Fluoride), 0.002 M), mixed
with 10% Triton X-100 and centrifuged (12,000 g for 30 min at 4 ◦C). The supernatants were collected, and
then the protein contents were analyzed with a micro Lowry reaction (DCTM Protein Assay #500-0116)
purchased from Bio-Rad Laboratories (Hercules, CA, USA). A Western blot analysis was performed by
using iNOS antibodies (BD Biosciences, CA, USA). The same amount of extracted protein from each
sample (30~40 µg) was loaded for the sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) immunoblot analysis. The separated proteins were electrophoretically transferred into
a nitrocellulose membrane (Amersham), which was then blocked with 5% BSA and 0.1% Tween for
60 min at room temperature. The membranes were incubated with the primary antibody overnight at
4 ◦C. The regions containing proteins were visualized by using ECL (Amersham ECL prime Western
blotting detection reagent # RPN2232) purchased from GE Healthcare Life Sciences (Buckinghamshire,
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UK). Each band was normalized by the corresponding value of α1-tubulin as an internal control.
A densitometric analysis was performed by Image J 1.36b (NIH) Software. The primary antibodies
against the proteins are listed in Table S3.
2.8. Statistical Analysis
A statistical analysis was performed by one-way ANOVA followed by Tukey’s post-hoc test
for multiple comparisons. A comparison of parameters between two groups was performed with
an unpaired Student’s t-test. The relationship between variables were assessed by Pearson’s correlation
coefficient. The presence of significant difference was estimate with the Sigmaplot v11.0 software (Systat
Software, Inc., San Jose, CA, USA), and p values below 0.05 (p < 0.05) were considered statistically
significant. All the data are presented as mean ± standard error of the mean (SEM).
3. Results
3.1. Food and Energy Intakes
A significant difference was observed between the S and HFDs groups for daily food intake
(g/100g BW), with the lowest values found for the Bch-fed rats (Figure 1A: Bch, 1.6 ± 0.3 g; VOO,
1.8 ± 0.2 g; S, 2.6 ± 0.3 g; p < 0.05). However, not significant differences for energy intake (kJ/day)
were observed between the groups (Figure 1B: S, 181.8 ± 19.9; VOO, 178.2 ± 15.4; Bch, 171.4 ± 22.8),
while the total weight gained was significantly higher in the Bch group (Bch, 151.9 ± 10.0 g; VOO,
101.6 ± 6.2 g; S, 73.6 ± 10.3 g; p < 0.05).
3.2. Glucose Tolerance Test (GTT) and Glycemic Control
No significant differences were found between groups in fasting plasma glucose (Figure 1E:
S, 63.8± 7.6 mg/dL; VOO, 83± 13 mg/dL; Bch, 63± 2.5 mg/dL) and insulin (Figure 1C: S, 0.5± 0.1 ng/mL;
VOO, 0.4 ± 0.1 ng/mL; Bch, 0.5 ± 0.1 ng/mL;). The effects of different diets on glucose tolerance were
established at the end of the experimental period by using GGT (Figure 1D).
The highest levels of plasma glucose were achieved after 20 min of i.p. injection in the S and
Bch groups (Figure 1E: S, 286.7 ± 34.9 mg/dL; VOO, 214.5 ± 43.4 mg/dL; Bch, 214.8 ± 15.7 mg/dL).
Nevertheless, the VOO animals achieved the highest plasma glucose at 60 min after i.p. injection
(S, 124.5 ± 11.7 mg/dL; VOO, 282.8 ± 58.5 mg/dL; Bch, 135 ± 12.3 mg/dL), and it remained elevated at
90 min.
Regarding the homeostasis model of insulin resistance, no significant differences were found
between the diets in the fasting ration of insulin/glucose (Figure 1D: S, 25.8 ± 9.5 µIU/mg; VOO,
13.7 ± 5.0 µIU/mg; Bch, 26.3 ± 5.5 µIU/mg), HOMA-IR (Figure 1F: S, 1.7 ± 0.4; VOO, 1.3 ± 0.3; Bch,
1.9 ± 0.5), HOMA2-%S (Figure 1G: S, 74.8 ± 19.8; VOO, 86.6 ± 22.6; Bch, 60.7 ± 19.1) or HOMA2-%B
(Figure 1H: S, 286.5 ±87.7; VOO, 159.6 ± 58.9; Bch, 317.2 ± 31.6).
3.3. Glucagon-Like-Peptide-1 and Dipeptidyl-Peptidase- 4 Activity
Though significant differences were not observed in circulating GLP-1 levels between the groups
(Figure 1I: S, 4.3 ± 1.0 pmol/L; VOO, 6.0 ± 0.7 pmol/L; Bch, 7.4 ± 1.3 pmol/L), the hepatic DPP4 family
activity (Figure 1J–K) was significantly higher in the high fat diets than in the control group. Namely,
the hepatic membrane-bound fraction showed the significantly highest values in the VOO-fed rats
compared with the S and Bch groups. (Figure 1K: S, 5.0 ± 0.5 pmol (×102)/min/mg protein; VOO,
7.8 ± 0.8 pmol (×102)/min/mg protein; Bch, 7.0 ± 0.4 pmol (×102)/min/mg protein) (Figure 1L: S,
0.8 ± 0.1 pmol (×102)/min/mg protein; VOO, 1.4 ± 0.2 pmol (×102)/min/mg protein).
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valuation of β-cell usefulness (% β-cell secretion) (HOMA2%B) (H); plasma glucagon-like peptide 1 
(GLP-1), expressed as pmol/L (I); and dipeptidyl-peptidase 4 (DPP4) activity in the liver-soluble 
fraction (J) and membrane-bound fraction (K), expressed as pmol/min/mg prot. S: standard diet, 
VOO: virgin olive oil diet, Bch: butter plus cholesterol diet. * indicates significant differences between 
VOO or Bch vs S, * p < 0.05. # indicates significant differences between VOO and Bch, # p < 0.05. 
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membrane-bound activity (Figure 2B). 
On the other hand, enkephalins have been widely implicated in feeding behavior, and these 
endogenous opioid peptides are hydrolyzed by the tyrosine aminopeptidase activity (TyrAP). Our 
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Figure 1. Means values ± standard errors of daily food intake, expressed as g/100 g Body Weight (A);
the intake of energy, expressed as kJ/day and total body weight gain, expressed as g (B); values of
plasma fasting insulin, expressed as ng/mL (C); ratio of plasma fasting insulin/glucose, expressed as
µIU/mg (D); values of glucose during test tolerance (GTT), expressed as mg/dL (E); homeostasis model
of insulin resistance (HOMA-IR), expressed as mg/dL x µIU/mL (F); an index for estimating sensitivity
to insulin (% insulin sensitivity) (HOMA2-%S) (G); an index of insulin secretion and a valuation
of β-cell usefulness (% β-cell secretion) (HOMA2%B) (H); plasma glucagon-like peptide 1 (GLP-1),
expressed as pmol/L (I); and dipeptidyl-peptidase 4 (DPP4) activity in the liver-soluble fraction (J) and
membrane-bound fraction (K), expressed as pmol/min/mg prot. S: standard diet, VOO: virgin olive oil
diet, Bch: butter plus cholesterol diet. * indicates significant differences between VOO or Bch vs. S,
* p < 0.05. # indicates significant differences between VOO and Bch, # p < 0.05.
3.4. Hepatic TRH-Degrading Pyroglutamate Aminopeptidase Activity and Tyrosine Aminopeptidase Activity
Previous studies have demonstrated that the effects of thyroid status on hepatic pGluAP and the
release of endogenous peptides as cyclo His-Pro (cHP) are determinant in insulin sensitivity and body
weight control [56,57]. In our results, HFDs significantly increased the soluble pGluAP activity in the
liver (Figure 2A: S, 1.0 ± 0.1 pmol (×102)/min/mg protein; VOO, 1.5 ± 0.0 pmol (×102)/min/mg protein;
Bch, 1.4 ± 0.0 pmol (×102)/min/mg protein). However, no differences were found in membrane-bound
activity (Figure 2B).
On the other hand, enkephalins have been widely implicated in feeding behavior, and these
endogenous opioid peptides are hydrolyzed by the tyrosine aminopeptidase activity (TyrAP). Our
results showed higher levels of soluble tyrosyl aminopeptidase activity in the liver of rats that were fed
with the Bch diet (Figure 2: S, 3.9± 0.5 pmol (×102)/min/mg protein; VOO, 4.5± 0.3 pmol (×102)/min/mg
protein; Bch, 6.2 ± 0.5 pmol (×102)/min/mg protein), but no significant differences were found in the
membrane-bound fraction.
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VOO or Bch vs. S. * p <0.05.
3.5. Hepatic Angiotensinases Activities
Figure 3 shows the metabolism of angiotensin peptides in the local renin–angiotensin system,
as well as the role of several aminopeptidases activities in soluble and membrane-bound fractions
(AspAP, GluAP, AlaAP and CysAP/IRAP). Significant differences were not observed in soluble or
membrane-bound fractions for aspartyl and glutamyl aminop ptidase activities betw en th diets
(Figure 3B–E). However, the VOO diet significantly increased the activity of alanyl aminopeptidase
activity (Figure 3G: S, 1.2 ± 0.1 pmol (×102)/min/mg protein; VOO, 2.4 ± 0.2 pmol (×102)/min/mg
protein; Bch, 1.6 ± 0.2 pmol (×102)/min/mg protein) and cystinyl aminopeptidase activity (Figure 3I: S,
1.9 ± 0.3 pmol (×102)/min/mg protein; VOO: 3.9 ± 0.2 pmol (×102)/min/mg protein; Bch: 2.7 ± 0.4 pmol
(×102)/min/mg protein) in the liver membrane-bound fraction.
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activity (GluAP) in liver-soluble (D) and membrane-bound (E) fractions; alanyl aminopeptidase activity
(AlaAP) in liver-soluble (F) and membrane-bound (G) fractions; and cystinyl aminopeptidase activity
(CysAP) in liver-soluble (H) and membrane-bound (I) fractions expressed as pmol/min/mg prot. S:
standard diet, VOO: virgin olive oil diet, Bch: butter plus cholesterol diet. * indicates significant
differences between VOO or Bch vs. S, * p < 0.05. # indicates significant differences between VOO and
Bch, # p < 0.05. ACE: angiotensin converting enzyme; IRAP: insulin regulated aminopeptidase.
3.6. Leucine Aminopeptidase and Gamma Glutamyl Transferase
Several indicators of hepatic function, such as GGT and leucine aminopeptidase (LeuAP),
were evaluated (Figure 4A–E). The butter plus cholesterol diet significantly increased hepatic
membrane-bound GGT activity compared with the S and VOO diets (Figure 4B: S, 0.8 ± 0.0 pmol
(×102)/min/mg protein; VOO, 09 ± 0.0 pmol (×102)/min/mg protein; Bch, 1.2 ± 0.1 pmol (×102)/min/mg
protein). Furthermore, a significant relationship was established between GGT membrane-bound
activity and the plasma lipid profile (total triglyceride) (Figure 4C).
Nutrients 2020, 12, 636 8 of 17 
aminopeptidase activity (AspAP) in liver-soluble (B) and membrane-bound (C) fractions; glutamyl 
aminopeptidase activity (GluAP) in liver-soluble (D) and membrane-bound (E) fractions; alanyl 
aminopeptidase activity (AlaAP) in liver-soluble (F) and membrane-bound (G) fractions; and cystinyl 
aminopeptidase activity (CysAP) in liver-soluble (H) and membrane-bound (I) fractions expressed as 
pmol/min/mg prot. S: standard diet, VOO: virgin olive oil diet, Bch: butter plus cholesterol diet. * 
indicates significant differences between VOO or Bch vs S, * p < 0.05. # indicates significant differences 
between VOO and Bch, # p < 0.05. ACE: angiotensin converting enzyme; IRAP: insulin regulated 
aminopeptidase. 
3.6. Leucine Aminopeptidase and Gamma Glutamyl Transferase 
Several indicators of hepatic function, such as GGT and leucine aminopeptidase (LeuAP), were 
evaluated (Figure 4A–E). The butter plus cholesterol diet significantly increased hepatic membrane-
bound GGT activity compared with the S and VOO diets (Figure 4B: S, 0.8 ± 0.0 pmol (×102)/min/mg 
protein; VOO, 09 ± 0.0 pmol (×102)/min/mg protein; Bch, 1.2 ± 0.1 pmol (×102)/min/mg protein). 
Furthermore, a significant relationship was established between GGT membrane-bound activity and 
the plasma lipid profile (total triglyceride) (Figure 4C). 
Soluble LeuAP activity also increased in the Bch group (Figure 4D: S, 4.6 ± 0.8 pmol 
(×102)/min/mg protein; VOO, 6.6 ± 0.4 pmol (×102)/ in/ g protein; Bch, 7.9 ± 0.8 pmol (×102)/min/mg 
protein), whereas m mbrane-bou d LeuAP activity was higher in the t o HFDs (Figure 4E: 4.0 ± 0.2 
pmol (×102)/min/mg protein; VOO, 5.3 ± 0.3 pmol (×102)/min/mg protein; Bch, 5.5 ± 0.2 pmol 
(×102)/min/mg protein). 
 
Figure 4. Means values ± standard errors of gamma glutamyl transferase activity (GGT) in liver-soluble
(A) and membrane-bound (B) fractions, expressed as pmol/min/mg prot., linear regressions established
between GGT and plasma triglycerides (TG) (C); and leucyl aminopeptidase activity (LeuAP) in
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Soluble LeuAP activity also increased in the Bch group (Figure 4D: S, 4.6 ± 0.8 pmol (×102)/min/mg
protein; VOO, 6.6 ± 0.4 pmol (×102)/min/mg protein; Bch, 7.9 ± 0.8 pmol (×102)/min/mg protein),
whereas membrane-bound LeuAP activity was higher in the two HFDs (Figure 4E: 4.0 ± 0.2 pmol
(×102)/min/mg protein; VOO, 5.3 ± 0.3 pmol (×102)/min/mg protein; Bch, 5.5 ± 0.2 pmol (×102)/min/mg
protein).
3.7. Plasma Nitric Oxide (NO) and Hepatic Inducible NO Synthase (iNOS)
In order to investigate the effects of HFDs on oxidative stress, the expression of hepatic iNOS was
determined by using a Western blot assay (Figure 5A,B), and the plasma NO concentrations (NOx)
were measured by the conversion of nitrate (NO3-) in to nitrite (NO2-) by nitrate reductase (Figure 5C).
The Bch-fed rats exhibited a significant increase in iNOS expression (Figure 5B: S, 1.0 ± 0.2; VOO,
1.3 ± 0.1; Bch: 2.3 ± 0.5). Moreover, the concentration NOx was significantly higher in the Bch group
compared with the S and VOO groups. Interestingly, the VOO group showed lower NOx levels than
the S group (Figure 5C: S, 1.4 ± 0.1 µmol/L; VOO, 0.9 ± 0.0 µmol/L; Bch, 2.1 ± 0.2 µmol/L).
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4. Discussion
High fat diets have demonstrated the ability to be a good model of obesity and metabolic syndrome
in laboratory animals models [6–8,56,58,59]. However, the efficiency in the use of energy also influences
the development of obesity in ro ents. A study by L u [7] demonstrated that obesity d velopment
was influenced by gend r and the effici ncy in the use of energy. In th current study, t e animals
were fed with two isoenergetic HFDs but with different degree of saturation in their fatty acids
(mainly monounsaturated in the VOO group and saturated in the Bch group) and minor components
(polyphenols in the VOO group and cholesterol in the Bch group). While the Bch animals achieved
a significantly higher body weight than the control group, the VOO rats did not show significant
differences with the control group (data not shown). Nevertheless, the greater gain of body weight in
the Bch rats were not associated with a higher food intake. Indeed, daily food intakes (g/100g BW)
were lower in the two HFDs at the end of the experimental period.
Regardless of the energetic-density of the diet, animals are usually able to adapt their food intake
and get the same amount of energy [60]. The differences in body weight gain between the HFDs may
be explained by the fact that saturated fatty acids show higher levels of energetic efficiency and are
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able to decrease the mitochondrial oxidative capacity in the liver and the skeletal muscle [61]. However,
the inclusion of VOO in the diet seems to have beneficial effects on body weight control [62,63], increase
diet-induced thermogenesis [64], regulate UCP1 (uncoupling protein 1) expression in the adipose tissue [65],
and enhance thermogenesis by increasing the UCP1 content in brown adipose tissue and increasing
noradrenaline and adrenaline secretions [66]. These results suggest that the unsaturated dietary fatty acids
and the quantity of dietary fat may have a significant effect on the regulation of thermogenic conditions.
At the same time, these effects could be related to the polyphenols present in VOO [13,67].
The differences in final body weight do not seem to be associated with altered values of fasting
plasma glucose and insulin in the three groups of animals. Nevertheless, our results showed differences
in the intraperitoneal glucose tolerance test (GTT). During the GTT, the higher levels of plasma glucose
were reached at 20 min after i.p. injection in the S and Bch groups. However, in VOO animals, the
maximum values were delayed until 90 min after i.p. injection, and they remained high at 120 min.
These results contradict with previous works [7,8,60], but the different index of insulin resistant that
was calculated in our animals (HOMA-IR, HOMA-%S and HOMA-%B) were similar in the three diets.
Still, mean values of fasting insulin/glucose and the HOMA2-%b were lower in the VOO group.
In the fed (postprandial) state, GLP-1 peptide has the ability to stimulate insulin secretion and
the synthesis of glycogen in the liver, thus reducing postprandial hyperglycemia. On the other hand,
the physiological inhibitory control of GLP-1 on gastric emptying and its contribution to the regulation
of food intake and satiety suggests that impaired secretion and/or activity of GLP-1 may be involved in
the pathogenesis of obesity. A previous study indicated that, in morbid obesity, the faster inactivation
of circulating GLP-1 could result in lower plasma levels of this peptide and could contribute to eating
behavior abnormalities [23]. Plasma DPP4 activity is the main factor that is implicated in the metabolism
of GLP-1, as well as its main regulator [23,68]. In the present study, an increase of the hepatic DPP4
family activity was only found in the VOO-fed rats, even if no differences in fasting plasma GLP-1
levels were obtained between the three diets, probably because of the rapid inactivation of this peptide.
Nevertheless, the high DPP4 activity in the VOO animals could have been related to high postprandial
GLP-1 levels, which in agreement with other previous works [17,69,70]. During the GTT, the stimulation
of the intestinal L cell did not take place, explaining the higher glucose values in the VOO group.
In addition to GLP-1, another peptide with important antidiabetic role able to improve insulin
sensitivity and body weight control is cyclo-histidine-proline (cHP) [43,71]. Cyclo-histidine-proline can
be found in hepatic cells [42,57], and it is a metabolic product of TRH by the activity of pyroglutamate
aminopeptidase (pGluAP) [57].
The role of pGluAP and cHP in the obesity is not yet clear, but cHP plus zinc is effective in
decreasing blood glucose concentrations in genetically obese (ob/ob), type 2 diabetic mice [72]. Moreover,
it has been reported that HFDs raise TRH expression [73] and alter pGluAP activity, effects that seem
to depend on the fat source [44]. Our results indicated that HFDs induced changes in hepatic TRH
metabolism, increasing the pGluAP activity in the soluble fraction of liver, with the consequence of the
overproduction of cHP.
Several orexigenic peptides, such as enkephalins (ENK), are able to modify the intake behavior
and the energy metabolism in animals [48,49]. A high fat diet changes the hypothalamic expression
of this peptide, increases the propensity to overeat, the gain of body weight, and the excess of white
adipose tissue [48]. Enkephalin concentration changes in the hepatic tissue and plasma during liver
disorders [47], and the liver cells can express Met-ENK immunoreactivity, suggesting that ENK is
an endogenous opioid that is produced by the liver [74]. Ours results suggest an increase in soluble
tyrosyl aminopeptidase activity (TyrAP), which was implicated in the degradation of ENK in the
livers of the Bch group, which could have been related to the differences in food intake and body
weight gain in these animals. In fact, ENK was recently proposed as a potential therapeutic peptide for
HFD-induced obesity and metabolic disorders [75].
The renin–angiotensin system (RAS) is an important regulator of blood pressure and water
balance. Beside the RAS, other local systems have been described in several tissues, including
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the liver [24,74,76,77]. Changes in the balance of different angiotensin bioactive peptides (AngII,
AngIII, AngIV, Ang2-10, and Ang1-7) have been implicated in different chronic diseases, such as
liver fibrosis, portal hypertension, hepatic tumors [37,78,79], and metabolic alterations, whereas the
blocking of angiotensin receptors has been shown to improve glycemic control and reduce hepatic
triglyceride levels [80]. The relative amounts of angiotensines are regulated by the activity of several
aminopeptidases, namely angiotensinases (Figure 3A). It is known that these activities are modulated
by dietary fat [5,29,30,54,81,82]. Previous results have demonstrated that liver angiotensinases are
altered by the thyroid status [83] and obesity [84,85]. The present results confirm the effect of a diet that
is enriched with virgin olive oil on liver aminopeptidase activity, increasing the activity of alanyl and
cystinyl aminopeptidase. Alanyl aminopeptidase (angiotensinase M) is implicated in the metabolism
of AngIII to AngIV [86], whereas cystinyl aminopeptidase (IRAP/AT4) has been described as the insulin
regulated aminopeptidase (IRAP) and also as the specific receptor to bind AngIV [83,85,87,88]. This
result could indicate an increase of local levels of AngIV, the peptide that binds to the AT4 receptor
that is colocalized with the glucose transporter GluT4 [27]. These changes were observed in the
membrane-bound fraction, which suggest a more specific functional role for these enzymes [87].
Otherwise, the diet that was enriched with butter and cholesterol increased peptidase activities
that have been widely proposed as hepatic biomarkers (GGT and LeuAP) [89,90]. Moreover, the activity
levels of the GGT in the liver were significant and positively correlated with plasma triglycerides
and total cholesterol. It has been reported that HFDs significantly increased GGT activity, whereas
antioxidants (vitamin E) and hypocaloric diets decreased GGT levels [91,92]. Published data have
shown that HFDs are the major triggers for oxidative stress [92], and both the cytoprotective role of
NO in the liver and hepatic iNOS expression could be an adaptive response to minimize inflammatory
injury, hepatic tumor, and cirrhosis [60]. Recently, studies that treated non-alcoholic fatty liver disease
(NAFLD) showed that the hepatic expression of iNOS was markedly increased in HFD-fed mice [40,93].
In our results, only animals that were fed with the Bch diet significantly increased the plasmatic levels
of nitrate, nitrites, and iNOS expression in the liver, probably as a response to the oxidative stress
damage. The main effects of HFDs on peptidase activities are summarized in Figure 6.
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Figure 6. Schematic diagram modeling the role of the high-fat diets (HFDs) that are associated
with changes in hepatic peptidases activities. (A) The virgin olive oil diet increased the hepatic
aminopeptidase activities that are related to glucose metabolism (membrane-bound dipeptidyl
peptidase 4 (DPP4), angiotensinase M (Alanine aminopeptidase), insulin-regulated-aminopeptidase
(IRAP)/CysAP). (B) The butter plus cholesterol diet (Bch) increased soluble and/or membrane-bound
activities that are implicated in the control of food intake (tyrosine aminopeptidase (TyrAP)), markers
of hepatic damage (leucine aminopeptidase (LeuAP) and gamma glutamyl transferase (GGT)), and the
expression of hepatic iNOS, which is involved the reactive oxidative stress (ROS) pathway and induces
an increase of plasmatic nitrogen oxides (NOx) levels.
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5. Conclusions
In conclusion, these results demonstrate that the metabolic response to a high fat diet that is
enriched with different fat sources could be related to changes in hepatic peptidases that are implicated
in the regulation of glucose metabolism and oxidative stress. The diet that was supplemented with
butter plus cholesterol altered peptidases activities that are associated with the impaired in the control
of food intake and hepatic damage, and it increased body weight. However, the diet that was
supplemented with virgin olive oil affected peptidases that are involved in glucose homeostasis (DPP4
and angiotensinases), but it did not alter body weight. Taken together, these results support the
beneficial effect of virgin olive oil on energy metabolism and body weight control. Further studies
should be performed in order to analyze the expression of key enzymes in fatty acids metabolism, and
its relation to peptidase activities.
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